Bordetella pertussis virulence antigens

Bordetella pertussis virulence antigens are a group of specialized proteins and toxins produced by the Gram-negative bacterium Bordetella pertussis, the causative agent of whooping cough (StatPearls, 2023). The primary antigens utilized in medical interventions include pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (Fim2 and Fim3) (CDC, 2022). These antigens facilitate the pathogen's attachment to the respiratory epithelium and disrupt host signaling pathways, such as the inhibition of G protein-coupled receptors by PT (Kilgore et al., 2016). In the context of pharmacology, these antigens are the active components of acellular pertussis vaccines, including DTaP and Tdap, which stimulate the host immune system to produce protective antibodies (FDA, 2023). These vaccines are designed to prevent the severe paroxysmal coughing and systemic complications associated with pertussis infection (NIH, 2021). Despite their success, the rise of pertactin-deficient strains and the relatively rapid waning of immunity compared to whole-cell vaccines present ongoing challenges for long-term disease control (Locht, 2017).

Other names

Pertussis antigensWhooping cough antigensAcellular pertussis vaccine componentsB. pertussis virulence factors

Active immunization inducing the production of neutralizing antibodies and memory B and T cells against bacterial attachment and toxin-mediated damage.